A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study

Trial Profile

A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 Status changed from completed to discontinued.
    • 07 Oct 2015 Accrual to date is 66% according to United Kingdom Clinical Research Network.
    • 04 Sep 2015 Accrual to date is 58% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top